Pharma R&D Today

New Report on Melanoma Research: 3 Key Findings

Posted on December 13th, 2019 by Tom Williams

The current state of melanoma research: insight & analytics, a new report released by Elsevier’s Life Sciences Professional Services, examines the landscape of melanoma R&D and reveals some very interesting findings.

Healthy China initiative emphasizes prevention

Posted on December 12th, 2019 by Xuanyan Xu

China has made huge strides in its national health since the 1950s when life expectancy was less than 45 years (today, it’s 76-79 years). I was born there in the 1980s and grew up through the beginning phase of economic reform and opening up to the world. The hospital infrastructure and quality of services has gotten much better, and there has been a growth in community healthcare providers and pharmacies. My parents and their generation say the entire healthcare system has improved tremendously. Government, universities and corporations have also been giving a great deal of attention to this area, especially with big data and AI trending.

PharmaPendium team collaborates with pharma companies on drug-drug interaction risk calculator

Posted on December 11th, 2019 by Marnix Wieffer

When taking a new drug, most patients’ chief concern is whether or not that drug is going to have the intended effect. They aren’t always thinking about what other drugs they might already be taking, and how those drugs could be affected by the new one.

FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool

Posted on December 3rd, 2019 by Marnix Wieffer

A leading cause of attrition of compounds in drug development, drug-induced liver injury (DILI) is also one of the top causes of drug withdrawals, restrictions and project terminations. DILI results when reactive metabolites – formed when certain orally administered drugs are metabolized in the liver – end up binding to cellular proteins and damaging liver cells.

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 by Xuanyan Xu

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

New Study Offers Insight into Alzheimer’s Disease Research Landscape

Posted on September 9th, 2019 by Tom Williams

The sixth leading cause of death in the U.S., and estimated to affect approximately 45 million people worldwide, Alzheimer’s is a progressive brain disease that causes memory loss and overall mental deterioration. Coinciding with World Alzheimer’s Month, Elsevier just released a report (which you can download here) analyzing Alzheimer’s research spanning the last 50 years in order to present a comprehensive overview of the research landscape for this irreversible condition.

About this Blog

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.